In our endeavor to recognize outstanding contributions in the field of translational medicine, the
The recipient of "The Excellence in Translational Medicine Award" will receive a $2,500 prize sponsored by Global Translational Medicine, Pfizer Global Research and Development to cover expenses for any meeting sponsored by a non-for-profit organization that is relevant to the goal of translational medicine and research. The competition, judged from the closeness of the scores, wherein 10 of the 15 papers evaluated were separated by ≤1 point and the top 4 papers by ≤0.4 points, was "fierce."
The best score and winner of the "Excellence in Translational Medicine Award" was Xinmei Zhu and colleagues from the University of Pittsburgh School of Medicine; Pittsburgh Cancer Center; Geneva University and Oncovir for the paper entitled: "Toll-like receptor-3 ligand poly-ICLC promotes the efficacy of peripheral vaccinations with tumor antigen-derived peptide epitopes in murine CNS tumor models" [2] .
Exemplifying the criteria for the "Excellence in Translational Medicine Award," Zhu et al. [2] proceeded from a potentially clinically relevant hypothesis through utilization of a sound research design with rigorous methodology to demonstrate with clarity that poly-ICLC (polyinosinic-polycytidylic acid stabilized with polylysine and carboxymethylcellulose) assisted antigen-specific peripheral vaccinations may represent an efficacious and safe therapeutic approach for central nervous system tumors.
The papers by the other three finalists: Kluger et al. [3] ; Provenzano et al. [4] and Grasso et al. [5] on the subjects of the x-linked inhibitor of apoptosis protein in metastatic melanoma, characterization of the p53-binding domains of the human polyomavirus BK tumor antigen, and ejaculatory disorders and the effects of α 1 -adrenoreceptor antagonists therapy, all translational related topics followed as listed, where but separated by a hair from the winning paper by Zhu et al. [2] .
With congratulations to Xinmei Zhu and colleagues [2] , the 1st "Excellence in Translational Medicine Award" is now history. We are hopeful this Award will serve to encourage other investigators devoted to improving the "bench to bedside" concept of translational medicine and initiatives in this direction. And, with the competition now open for the 2nd "Excellence in Translational Medicine Award," we very much look forward to the opportunity of selecting next year's winning paper.
